뒤로
Multicell Technologies Inc(MCET) 가격
MCET 주가 차트
MCET 수입
Multicell Technologies Inc
$0
0%
$0
종가: Feb 13, 16:00:00 GMT-5
$0
0%
$0
애프터마켓: Feb 13, 20:00:00 GMT-5
아직 데이터 없음Earnings FAQ
MCET의 최근 주당순이익(EPS)은 예상과 비교하여 어떤가요?
Multicell Technologies Inc MCET의 지난 분기 매출 실적은 어땠나요?
Multicell Technologies Inc의 매출 추정치는 얼마인가요?
Multicell Technologies Inc의 수익 품질 점수는 얼마인가요?
Multicell Technologies Inc는 언제 수익을 보고하나요?
Multicell Technologies Inc의 예상 수익은 얼마인가요?
Multicell Technologies Inc은 수익 기대치를 충족했나요?
주요 통계
이전 종가
$0
시가
$0
일일 범위
$0 - $0
52주 범위
$0 - $0
거래량
20.0K
평균 거래량
0
EPS(TTM)
-0.00
배당수익률
--
시가총액
$50.0K
MCET란 무엇인가요?
MultiCell Technologies, Inc. is a clinical-stage biopharmaceutical company, which engages in the provision of novel therapeutics and discovery tools that address unmet medical needs for the treatment of neurological disorders, hepatic disease and cancer. The company is headquartered in Woonsocket, Rhode Island. The firm and its subsidiaries are developing therapeutics and discovery tools for the treatment of neurological disorders, hepatic disease, cancer and interventional cardiology, and peripheral vessel applications. The firm's portfolio of lead drug candidates is in various stages of discovery optimization, and preclinical and clinical development, and includes MCT-125, MCT-465, MCT-475 and MCT-485. MCT-125 is a Phase II therapeutic candidate for the treatment of primary multiple sclerosis-related fatigue. MCT-465 is a preclinical synthetic double-stranded ribonucleic acid (dsRNA) therapeutic candidate and potent immune enhancer for the treatment of solid tumor cancers. MCT-475 is a discovery-stage antibody therapeutic candidate used in combination with dsRNA for the treatment of solid tumor cancers. MCT-485 is a discovery-stage dsRNA therapeutic candidate for the treatment of certain cancers.